2024
Prevalence of metabolic comorbidities and viral co-infections in monoclonal gammopathy: a retrospective analysis
Muradashvili T, Yu M, Browning S, Bar N, Gorshein E, Parker T, Neparidze N. Prevalence of metabolic comorbidities and viral co-infections in monoclonal gammopathy: a retrospective analysis. Leukemia 2024, 38: 2281-2283. PMID: 39164408, DOI: 10.1038/s41375-024-02380-x.Peer-Reviewed Original Research
2023
P-098 Prevalence of metabolic comorbidities and viral co-infections in monoclonal gammopathy: a retrospective analysis
Muradashvili T, Yu M, Neparidze N. P-098 Prevalence of metabolic comorbidities and viral co-infections in monoclonal gammopathy: a retrospective analysis. Clinical Lymphoma Myeloma & Leukemia 2023, 23: s88-s89. DOI: 10.1016/s2152-2650(23)01716-0.Peer-Reviewed Original Research
2018
Antigen-mediated regulation in monoclonal gammopathies and myeloma
Nair S, Sng J, Boddupalli CS, Seckinger A, Chesi M, Fulciniti M, Zhang L, Rauniyar N, Lopez M, Neparidze N, Parker T, Munshi NC, Sexton R, Barlogie B, Orlowski R, Bergsagel L, Hose D, Flavell RA, Mistry PK, Meffre E, Dhodapkar MV. Antigen-mediated regulation in monoclonal gammopathies and myeloma. JCI Insight 2018, 3: e98259. PMID: 29669929, PMCID: PMC5931125, DOI: 10.1172/jci.insight.98259.Peer-Reviewed Original ResearchConceptsMultiple myelomaPlasma cellsGaucher diseaseAntigenic stimulationMonoclonal gammopathyAntigen-driven stimulationMonoclonal IgClonal IgB cell receptorSingle tumor cellsPatient cohortUndetermined significanceVivo responsivenessMalignant cloneGammopathyTumor growthMonoclonal tumorsCell receptorTumor cellsAntigenGene expression profilingStimulationClonal natureMyelomaTumors
2017
Changes in bone marrow innate lymphoid cell subsets in monoclonal gammopathy: target for IMiD therapy
Kini Bailur J, Mehta S, Zhang L, Neparidze N, Parker T, Bar N, Anderson T, Xu ML, Dhodapkar KM, Dhodapkar MV. Changes in bone marrow innate lymphoid cell subsets in monoclonal gammopathy: target for IMiD therapy. Blood Advances 2017, 1: 2343-2347. PMID: 29296884, PMCID: PMC5729633, DOI: 10.1182/bloodadvances.2017012732.Peer-Reviewed Original ResearchAsymmetric Deep Stromal Keratopathy in a Patient With Multiple Myeloma
Tainsh LT, Coady PA, Sinard JH, Neparidze N, Meskin SW, Adelman RA, Chow J. Asymmetric Deep Stromal Keratopathy in a Patient With Multiple Myeloma. Cornea 2017, 36: 372-374. PMID: 28079685, DOI: 10.1097/ico.0000000000001139.Peer-Reviewed Original ResearchConceptsMultiple myelomaVisual acuityRight eye 2 yearsDeep stromal opacitiesEye 2 yearsPatient's visual acuityDiagnosis of IgGParaproteinemic keratopathyInitial presentationStromal lesionsStromal opacityCase reportHematologic workupMonoclonal gammopathyAsymmetric presentationUnusual casePosterior stromaMyelomaKeratopathyPatientsDiagnosisPresentationLiterature reviewKeratoplastyAcuity
2009
Waldenstrom's macroglobulinemia: Recent advances in biology and therapy.
Neparidze N, Dhodapkar MV. Waldenstrom's macroglobulinemia: Recent advances in biology and therapy. Clinical Advances In Hematology And Oncology 2009, 7: 677-81, 687-90. PMID: 20040909, PMCID: PMC3612541.Peer-Reviewed Original ResearchConceptsWaldenstrom's macroglobulinemiaLymphoplasmacytic cellsClonal lymphoplasmacytic cellsHigh-dose chemotherapyBone marrow infiltrationInternational Staging SystemStem cell transplantationB-cell disordersComplete remissionFrontline therapyObjective responseMarrow infiltrationCell transplantationStaging systemTherapeutic armamentariumMonoclonal gammopathyNovel agentsMacroglobulinemiaTherapyProteasome inhibitorsDisease biologyNucleoside analoguesPromising activityRecent studiesRecent advances